Literature DB >> 8040256

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?

M Sasahara1, E W Raines, A Chait, T E Carew, D Steinberg, P W Wahl, R Ross.   

Abstract

Lipoprotein oxidation is believed to play an important role in atherogenesis. To investigate whether inhibition of oxidation of low density lipoprotein (LDL) would alter atherogenesis in the nonhuman primate, we administered probucol, a potent antioxidant, to Macaca nemestrina fed a high-fat, high-cholesterol diet. Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos. To evaluate the antioxidant effect of probucol, the resistance of isolated plasma LDL to in vitro oxidation was evaluated. Probucol significantly increased the resistance of LDL to oxidative modification, as shown by an increase in the lag time required for conjugated diene formation. Lesions in the probucol-treated animals appeared less mature, and increased accumulation of lipid was observed in smooth muscle cells. Comparison of all control and probucol-treated monkeys demonstrated that intimal lesion areas in the thoracic aortas of the probucol-treated monkeys were reduced by 43% (P < 0.0001), but no significant difference in lesion area was found in the abdominal aortas or in the iliac arteries. However, the lag phase of conjugated diene formation was not prolonged in 2 of the 8 probucol-treated animals. A plot of intimal lesion size versus lag phase of all 16 animals showed a trend that lesion size was inversely related to oxidation resistance for all anatomic sites. The strong inverse relationship between intimal lesion size and resistance of LDL to oxidation supports a role for lipoprotein oxidation in the development and progression of lesions of atherosclerosis. The possibility that some of the effect is due to other biological properties of probucol cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040256      PMCID: PMC296293          DOI: 10.1172/JCI117301

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis.

Authors:  A J Verlangieri; M J Bush
Journal:  J Am Coll Nutr       Date:  1992-04       Impact factor: 3.169

2.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Authors:  A Chait; R L Brazg; D L Tribble; R M Krauss
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

3.  Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism.

Authors:  J R Wetterau; K A Combs; H W Albers; G Lamkin; E A Stein; R L Barnhart; E M Chi; R L Jackson; J A Harmony
Journal:  Horm Metab Res       Date:  1992-06       Impact factor: 2.936

4.  Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.

Authors:  Y Nagano; T Nakamura; Y Matsuzawa; M Cho; Y Ueda; T Kita
Journal:  Atherosclerosis       Date:  1992-02       Impact factor: 5.162

5.  Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases.

Authors:  T Nakamura; Y Ueyama; T Funahashi; S Yamashita; K K Takemura; M Kubo; K Yamada; Y Matsuzawa
Journal:  Atherosclerosis       Date:  1992-02       Impact factor: 5.162

6.  Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.

Authors:  S Parthasarathy
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

7.  Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits.

Authors:  K O'Brien; Y Nagano; A Gown; T Kita; A Chait
Journal:  Arterioscler Thromb       Date:  1991 May-Jun

8.  Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine.

Authors:  C P Sparrow; T W Doebber; J Olszewski; M S Wu; J Ventre; K A Stevens; Y S Chao
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.

Authors:  P D Reaven; S Parthasarathy; W F Beltz; J L Witztum
Journal:  Arterioscler Thromb       Date:  1992-03

Review 10.  Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: a perspective.

Authors:  J D Barth; A C Arntzenius
Journal:  Eur Heart J       Date:  1991-08       Impact factor: 29.983

View more
  19 in total

1.  Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.

Authors:  K Ishikawa; M Navab; N Leitinger; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Increased atherosclerosis in hyperlipidemic mice deficient in alpha -tocopherol transfer protein and vitamin E.

Authors:  Y Terasawa; Z Ladha; S W Leonard; J D Morrow; D Newland; D Sanan; L Packer; M G Traber; R V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Factors affecting resistance of low density lipoproteins to oxidation.

Authors:  O Ziouzenkova; S P Gieseg; P Ramos; H Esterbauer
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

4.  Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Authors:  S H Zhang; R L Reddick; E Avdievich; L K Surles; R G Jones; J B Reynolds; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 5.  Atherosclerosis as disease of redox-sensitive genes.

Authors:  R W Alexander
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

Review 6.  New approaches to the prevention of atherosclerosis.

Authors:  M Naito; T Hayashi; A Iguchi
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

7.  Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro.

Authors:  R Menéndez; R Más; A M Amor; R M González; J C Fernández; I Rodeiro; M Zayas; S Jiménez
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

8.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.

Authors:  C Napoli; F P D'Armiento; F P Mancini; A Postiglione; J L Witztum; G Palumbo; W Palinski
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

9.  Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice.

Authors:  Yeon Suk Jung; Jung Hwa Park; Hyunha Kim; So Young Kim; Ji Young Hwang; Ki Whan Hong; Sun Sik Bae; Byung Tae Choi; Sae-Won Lee; Hwa Kyoung Shin
Journal:  Acta Pharmacol Sin       Date:  2016-06-27       Impact factor: 6.150

Review 10.  Antioxidants: the good, the bad and the ugly.

Authors:  Jean-Claude Tardif
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.